U.S. Markets closed
  • S&P 500

    3,832.19
    +6.86 (+0.18%)
     
  • Dow 30

    30,971.74
    -125.52 (-0.40%)
     
  • Nasdaq

    11,322.37
    +194.52 (+1.75%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    110.30
    +1.87 (+1.72%)
     
  • Gold

    1,807.40
    +5.90 (+0.33%)
     
  • Silver

    19.86
    +0.19 (+0.98%)
     
  • EUR/USD

    1.0428
    +0.0001 (+0.0104%)
     
  • 10-Yr Bond

    2.8090
    -0.0800 (-2.77%)
     
  • Vix

    26.70
    -2.01 (-7.00%)
     
  • GBP/USD

    1.2109
    +0.0006 (+0.0484%)
     
  • USD/JPY

    135.6670
    +0.4920 (+0.3640%)
     
  • BTC-USD

    20,577.68
    +749.19 (+3.78%)
     
  • CMC Crypto 200

    441.11
    +1.09 (+0.25%)
     
  • FTSE 100

    7,232.65
    +64.00 (+0.89%)
     
  • Nikkei 225

    26,153.81
    +218.19 (+0.84%)
     

Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Avrobio Inc (NASDAQ: AVROannounced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in infantile-onset Pompe disease.

  • Pompe disease is a lysosomal disorder caused by a mutation in the GAA gene. The lack of the enzyme encoded by GAA results in a toxic buildup of glycogen throughout the body and central nervous system.

  • The results demonstrate that gene therapy using hematopoietic stem cells (HSC) significantly reduced the toxic accumulation of glycogen in a mouse model of Pompe disease, including in cardiac and skeletal muscle and the central nervous system (CNS).

  • Also See: AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study.

  • Eight months post-infusion, substrate levels in multiple treated tissues were nearly indistinguishable from normal mice.

  • Additionally, new data from a separate study show that human HSCs were efficiently transduced, producing robust quantities of transgene product and GAA enzyme activity.

  • AVROBIO plans to engage with regulatory agencies on the clinical development strategy for AVR-RD-03 in 2022 and plans to initiate a clinical trial in 2023.

  • Price Action: AVRO shares are down 4.38% at $0.79 during the market session on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.